Blog

Q: Q. Does the existing medical field have unique biological indicators to separate asthma from COPD?

A. FeNO and IgE biomarkers primarily exist in asthma patients, yet CRP, SP-D, and fibrinogen are identified most often in COPD cases.

Q: Q. What options exist for non-legally intrusive assessments of respiratory biomarkers?

A. A simple breath analysis of exhaled air permits non-invasive measurement of FeNO levels and volatile organic compounds (VOCs) as indicators of airway inflammation.

Q: Q. Can biomarkers detect early COPD?

A. Through AAT deficiency testing, generalized risk factors for COPD become identifiable, while early disease progression shows itself through increased levels of CRP and fibrinogen.

Q: Q. What role do biomarkers serve at present in clinical medical practices?

A. Medical facilities use biomarkers FeNO and eosinophils, while CRP and AAT testing are used to properly diagnose and manage asthma and COPD patients.

Blog
Biomarkers for Respiratory Diseases: From Asthma to COPD

Frequently Asked Questions

Q. Can biomarkers predict asthma attacks?

A. The combination of measured FeNO levels, eosinophil counts, and periostin levels within the body indicates significant airway inflammation and increases asthma exacerbation potential.